Treatment-resistant depression (TRD) is depression that has not improved enough after at least two antidepressant treatments taken at an adequate dose for long enough. It does not mean recovery is impossible. Medication changes, psychotherapy, and specialized treatments such as TMS, ECT, and esketamine remain available.
Understanding how clinicians assess treatment resistance can help you discuss next steps. It can also help you see another unsuccessful prescription for what it is: information for your care team, not a personal failure.
What is treatment-resistant depression?
Treatment-resistant depression generally means major depression has not responded adequately to at least two antidepressants taken at appropriate doses for a sufficient time. Definitions vary, and TRD is not listed as a separate diagnosis in the DSM-5-TR. So a clinician reviews the details of each treatment rather than simply counting prescriptions.
An incomplete trial, or a medication stopped early because of side effects, may need a different interpretation. Those situations do not necessarily mean the depression is resistant to treatment.
How common is treatment-resistant depression?
Treatment-resistant depression is more common than many people realize. Researchers estimate that at least 30% of people with depression meet the definition of TRD.
Signs your depression treatment may not be working
The symptoms of treatment-resistant depression are those of depression: persistent sadness, loss of interest, fatigue, sleep or appetite changes, and difficulty concentrating. Some people improve partly but still struggle with everyday responsibilities.
Talk to your prescriber if any of these sound familiar:
You have tried two or more antidepressants without enough relief.
Treatment helped a little, but you still don’t feel like yourself.
Side effects have made it hard to stay on a medication.
Improvement fades, or symptoms keep coming back.
A good assessment considers both your symptoms and how well you are functioning, not just whether you feel slightly better than before. If your depression has not improved after several treatments, ask about an evaluation with a psychiatrist.
What causes treatment-resistant depression?
There is no single established cause of treatment resistance. Biological differences, coexisting illnesses, ongoing stress, and treatment-related barriers may all contribute. A reassessment looks for factors that can be addressed, including whether the original diagnosis and treatment plan still fit.
A clinician may explore:
Treatment exposure: Whether the medication reached an appropriate dose and was taken long enough to judge whether it helped.
Practical barriers: Side effects, cost, or difficulty following the schedule that interrupted treatment.
Other health conditions: Thyroid disorders, chronic pain, or other illnesses that can cause or worsen depressive symptoms.
Diagnostic differences: Whether bipolar disorder or another mental health condition requires a different approach.
Substances and circumstances: Alcohol or drug use, medication interactions, and ongoing life stressors.
Researchers note that some depression that looks treatment-resistant is actually “pseudo-resistant.” In these cases a trial was too short, the dose too low, or the medicine was not taken consistently.
These questions are not about assigning blame. Tell your clinician what actually happened during treatment, including missed doses or symptoms you felt uncomfortable mentioning. That information helps separate a treatment that did not work from one that never had a fair chance.
Treatment options for treatment-resistant depression
Next steps may include adjusting or switching medication, adding another treatment, strengthening psychotherapy, or considering brain stimulation or esketamine. There is no single sequence that suits everyone. Decisions should reflect your previous responses, symptom severity, medical risks, preferences, and the practical demands of each treatment.
Medication adjustments and add-on treatments
A prescriber may optimize your current antidepressant, switch to another, or add a medication to improve its effect. This add-on approach is called augmentation. Options may include lithium or certain antipsychotics; aripiprazole, brexpiprazole, and extended-release quetiapine are FDA-approved as add-ons to an antidepressant.
Each strategy brings different side effects and monitoring needs. Ask why it fits your situation and how benefit will be measured.
Do not increase, combine, or abruptly stop medications yourself. Stopping an antidepressant suddenly can cause withdrawal symptoms. If side effects make it hard to continue, contact your prescriber to discuss a safer adjustment plan.
Psychotherapy as an active treatment
Psychotherapy remains useful even when medication has not provided enough relief. Cognitive behavioral therapy (CBT) addresses patterns of thinking and behavior. Interpersonal therapy focuses on relationship difficulties. If past counseling felt unhelpful, ask whether a different approach or therapist would suit you better, rather than assuming all therapy is the same.
Transcranial magnetic stimulation (TMS)
Transcranial magnetic stimulation (TMS) uses magnetic pulses to stimulate targeted areas of the brain. It does not require anesthesia, but it usually involves repeated appointments over several weeks. Headache or scalp discomfort can occur, and clinicians screen for safety considerations before treatment.
Electroconvulsive therapy (ECT)
Electroconvulsive therapy (ECT) produces a controlled seizure under anesthesia. It may be considered for severe depression, especially when a rapid response is needed, and it can help when other treatments have not worked. Memory problems and confusion are important risks to discuss, and ongoing treatment is often needed to maintain improvement.
Esketamine (Spravato) nasal spray
Esketamine nasal spray is FDA-approved for adults with treatment-resistant depression, either alone or with an oral antidepressant. The FDA approved it as a standalone treatment in January 2025.
Esketamine is given under supervision through a restricted safety program, with monitoring for at least two hours after each dose. Risks include sedation, dissociation, breathing problems, and increased blood pressure. It is not a take-home treatment.
How to prepare for a more useful treatment review
Bring a brief treatment history to your next appointment. Include medication names, doses if known, approximate dates, benefits, side effects, and why each treatment ended. Add any therapy approaches you have tried and any supplements or nonprescription products you use.
Use this checklist to guide the conversation:
Clarify the assessment: “Were my previous treatments adequate trials?”
Define improvement: Choose meaningful goals, such as returning to work or reconnecting with friends.
Compare the options: Ask about likely benefits, risks, monitoring, appointment frequency, and costs.
Set a review point: Agree on when to evaluate progress and whom to contact if symptoms worsen.
Everyday habits that can support treatment
Regular sleep, manageable movement, nourishing meals, and supportive contact with others can complement care. Start with realistic actions rather than an overwhelming lifestyle overhaul. These habits support well-being. They do not replace professional treatment, and persistent depression is not your fault.
Treatment-resistant depression FAQ
Can treatment-resistant depression be treated?
Yes. “Treatment-resistant” describes how depression has responded to past treatments, not what will happen next. Many people improve with a different medication strategy, psychotherapy, brain stimulation, or esketamine.
How many medications before depression is considered treatment-resistant?
Most clinicians use at least two antidepressants taken at an adequate dose for long enough. Definitions vary, so your clinician will look at the details of each trial, not just the number.
Is esketamine the same as ketamine?
Esketamine is a form of ketamine. The nasal spray (Spravato) is FDA-approved for treatment-resistant depression and is given only in certified settings under monitoring. Ketamine infusions for depression are used off-label, which means that use is not FDA-approved.
Is TMS or ECT better for treatment-resistant depression?
It depends on your situation. ECT has the longest track record and is often considered for severe depression or when a fast response is needed. TMS does not require anesthesia and is less likely to affect memory. Your clinician can help you weigh the trade-offs.
Should I see a psychiatrist for treatment-resistant depression?
If your depression has not improved after two or more treatments, a psychiatrist can review your history, confirm the diagnosis, and discuss specialized options.
Keep the focus on the next step
Treatment-resistant depression calls for a careful review and a personalized plan, not a conclusion that nothing can help. If symptoms persist, ask about a specialist assessment and a shared plan for evaluating the next treatment. You do not need to work through every option at once.
If you are having thoughts of suicide or urges to harm yourself, call or text 988 in the United States for immediate support. Call 911 in a life-threatening emergency.